Change over period: —
NSE · MEDANTA
MEDANTA
-4.8% from the 52-week high · +49.5% above the low
Global Health Ltd. engages in the provision of healthcare, pathology, and other medical services. The company is headquartered in New Delhi, Delhi. The company went IPO on 2022-11-16. Medanta delivers advanced, end-to-end healthcare in Delhi, Gurugram, Indore, Ranchi, Patna and Lucknow through its network of five hospitals, six Mediclinic, diagnostic laboratories, homecare and telemedicine services. The company provides treatments for coronary artery disease, head and neck cancer, acute myeloid leukemia, epilepsy, hip fracture, Parkinson's disease, refractive error, prostate cancer, chronic kidney disease, cerebral stroke, sepsis, liver cirrhosis, rheumatoid, arthritis, hypertension, diabetes, bronchial asthma, stomach cancer, and chronic otitis media. Medanta specializes in cardiac surgery, nephrology, urology, andrology, dermatology, ophthalmology, radiology and imaging, dental sciences, and interventional cardiology, among others. Its facilities and services include medicine delivery, air ambulance, patient support services, and others.
The short version. MEDANTA reported revenue of ₹1,469 crore for Sep 2026, up 33.7% from a year earlier. Net profit was ₹219 crore (up 38.6% year on year). Return on equity was 14.1% in Mar 2026. Promoter holding was 33.0% in Sep 2026, down 0.03 points over 8 quarters.
1 · The price
How has the stock traded?
MEDANTA trades 4.8% below its 52-week high and 49.5% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹1,469 cr.
Sep 2026 net profit of ₹219 cr.
0.5 pts higher than a year earlier.
Revenue compounded at 17.8% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1469 | 1304 | 1159 | 1121 | 1099 | 1031 | 931 | 943 |
| Net profit | 219 | 159 | 144 | 95 | 158 | 159 | 101 | 143 |
| Net margin % | 14.9 | 12.2 | 12.4 | 8.5 | 14.4 | 15.4 | 10.9 | 15.1 |
| EPS (₹) | 8.15 | 5.9 | 5.36 | 3.54 | 5.89 | 5.92 | 3.78 | 5.32 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | 4410 | 3692 | 3275 | 2694 |
| Net profit | 556 | 481 | 478 | 326 |
| Net margin % | 12.6 | 13.0 | 14.6 | 12.1 |
| EPS (₹) | 20.7 | 17.92 | 17.81 | 12.16 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 14.1% in Mar 2026; debt to equity is 0.30.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 14.1 | 14.2 | 16.5 | 13.4 |
| Return on capital % | 15.0 | 17.2 | 19.0 | 14.9 |
| EBITDA margin % | 22.6 | 24.0 | 26.1 | 24.5 |
| Net margin % | 12.3 | 12.8 | 14.3 | 11.8 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 17.8% | — |
| Profit CAGR | 19.5% | — |
4 · The owners
Who holds it, and are they adding?
Down 0.03 pts over 8 quarters.
Down 2.56 pts over 8 quarters.
Up 6.5 pts over 8 quarters.
+36 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 33.03 | 33.03 | 33.01 | 33.01 | 33.01 | 33.01 | 33.0 | 33.0 | -0.03 |
| FII | 12.47 | 11.76 | 11.54 | 11.4 | 10.53 | 10.15 | 9.46 | 9.91 | -2.56 |
| DII | 10.51 | 11.93 | 12.2 | 12.98 | 14.0 | 14.76 | 16.89 | 17.01 | +6.5 |
| Public | 43.98 | 43.28 | 43.19 | 42.55 | 42.4 | 42.0 | 40.56 | 39.97 | -4.01 |
Mutual fund holdings · Oct 2026
152 schemes hold this stock
116 the month before.
- Invesco India Pharma and Healthcare Fund5.96% of NAV
- Groww BSE Hospitals ETF5.2% of NAV
- Invesco India Focused Fund4.1% of NAV
- Invesco India Mid cap Fund3.67% of NAV
- UTI - Healthcare Fund3.37% of NAV
- HSBC Consumption Fund3.0% of NAV
- Motilal Oswal Innovation Opportunities Fund2.91% of NAV
- ITI Pharma and Healthcare Fund2.65% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for MEDANTA are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Healthcare Services stocks
Quick answers
Common questions about MEDANTA
What is the MEDANTA share price?
MEDANTA (MEDANTA) last closed at ₹1,478.30, up 2.9% on the day. Its 52-week range is ₹961.10 to ₹1,508.90.
What is the market cap of MEDANTA?
MEDANTA has a market capitalisation of about ₹38,578 crore. Its price-to-earnings ratio is 62.9.
How are MEDANTA's latest results?
MEDANTA reported revenue of ₹1,469 crore for Sep 2026, up 33.7% from a year earlier. Net profit was ₹219 crore (up 38.6% year on year). Return on equity was 14.1% in Mar 2026. Promoter holding was 33.0% in Sep 2026, down 0.03 points over 8 quarters.
Who owns MEDANTA?
As of Sep 2026, shareholding was: Promoter 33.0%, FII 9.91%, DII 17.01%, Public 39.97%.
How many mutual funds hold MEDANTA?
152 mutual fund schemes held MEDANTA in October 2026. That compares with 116 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 22 Aug 2025 · Final Dividend - Rs. 0.5
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.